Verdiva Bio
Mandi Conklin is an experienced professional in clinical project management and trial master file (TMF) oversight. Currently serving as Senior Manager of TMF and Clinical Project Management at Verdiva Bio, Mandi has previously held key roles at Aiolos Bio, EQRx, IQVIA, Clinical Reference Laboratory, and Quintiles. Mandi's expertise includes developing TMF standard operating procedures, ensuring quality oversight of TMF records, and collaborating with various teams to maintain compliance with GCP records management. Mandi holds a Bachelor of Science in Business Administration from Western Governors University and an Associate's Degree in Applied Science from Vatterott College.
This person is not in the org chart
This person is not in any offices
Verdiva Bio
1 followers
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit www.verdivabio.com.